Delving deeper into stem cell treatment for ASD: In May 2020 the journal Molecular Autism published the following review of clinical trial data for Stem Cell treatment (MSC or SCT) for ASD: Cell Therapy Approaches to Autism: a Review of Clinical Trial Data. In his review of the literature, Dr Price brings to light many of the questions and challenges regarding SCT for ASD:
- Stem Cell therapy is being marketed shamelessly as a miracle autism cure. Families seeking answers for their children may be barraged by social media posts, texts, emails, and other ‘direct to consumer’ ads from questionable clinics that promise more than they can deliver and at great expense to families. SCT providers do not acknowledge the experimental nature of the therapy, and the lack of regulatory review of the treatment process.
- The global clinical research enterprise is important to provide safeguards to families of children with ASD with regard to Stem Cell Therapy and more broadly. While SCT clinical research is promising, it remains at a very early stage, with a very limited number of participants and without a strong track record of success. Many SCT clinical studies lack a clear therapeutic target and often have stopped in the middle for unspecified reasons.
- In terms of the best clinical research for SCT, a variety of protocols have been examined varying sources of stem cells (eg. donor cells, frozen umbilical cord blood cells from the child himself, fresh cells harvested from the child’s bone marrow etc) and methods of administration – so it is difficult to compare the data between the studies. Dr Price gives his suggestions for rectifying the situation with further study based on clear therapeutic targets.

Cell-El Ltd. is specifically focused on rectifying the state of SCT clinical research for ASD. We believe that further study is warranted with well-researched treatment protocols and, of course, full regulatory approval. As far as a clear therapeutic target – Cell-El has designed a comprehensive pre-treatment diagnostic protocol focused on identifying a baseline understanding of what biologically we are treating when administering SCT – what the biological issues exist pre-treatment and how they possibly change – with objective biological measures. Cell-El Ltd. strives to bring to the ASD children and their families state of the art, science-backed data that to open up new, reliable, innovative treatment options.
Help Us Help You
Better diagnostics for ASD based on laboratory-measured objective biomarkers can possibly enable researchers and clinicians to provide more precise and personalized treatment. You too can make a difference in the lives of children with ASD and their families by joining the Cell-El study. Cell-El is recruiting for two of our study cohorts. We are recruiting mothers, and their infants aged 10-19 months who have not been diagnosed with ASD but who have a sibling diagnosed with ASD. Cell-El is also recruiting children diagnosed with ASD between the ages of 2-18 years old whose parents are planning to take them privately to a clinic offering Stem Cell treatment for ASD.
Please contact Leah at [email protected] or fill out the form to find out about eligibility to participate in our diagnostic study and please help spread the word about the Cell-El study. Sharing our study will enable our important biomarker diagnostic tool to be integrated into autism treatment as quickly as possible.